HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.
作者信息
Becher Oren J
机构信息
Division of Hematology, Oncology and Stem Cell Transplant, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.
Malnati Brain Tumor Center and Lurie Cancer Center, Northwestern University, Chicago, Illinois.
出版信息
Neuro Oncol. 2019 Sep 6;21(9):1091-1092. doi: 10.1093/neuonc/noz115.
Abstract
摘要
相似文献
1
HDAC inhibitors to the rescue in sonic hedgehog medulloblastoma.组蛋白去乙酰化酶抑制剂拯救音猬因子型髓母细胞瘤。
Neuro Oncol. 2019 Sep 6;21(9):1091-1092. doi: 10.1093/neuonc/noz115.
2
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.一项大规模药物筛选发现，选择性抑制 I 类组蛋白去乙酰化酶可作为治疗 SHH 型髓母细胞瘤的潜在治疗选择。
Neuro Oncol. 2019 Sep 6;21(9):1150-1163. doi: 10.1093/neuonc/noz089.
3
HDACs and MYC in medulloblastoma: how do HDAC inhibitors control MYC-amplified tumors?髓母细胞瘤中的组蛋白去乙酰化酶（HDACs）与MYC：HDAC抑制剂如何控制MYC扩增的肿瘤？
Neuro Oncol. 2021 Feb 25;23(2):173-174. doi: 10.1093/neuonc/noaa292.
4
Turning off the switch in medulloblastoma: the inhibitory acetylation of an oncogene.关闭髓母细胞瘤中的开关：一种致癌基因的抑制性乙酰化
Cell Cycle. 2010 Jun 1;9(11):2047-8. doi: 10.4161/cc.9.11.11860.
5
Targeted therapy done right: Direct sonic hedgehog inhibition for sonic hedgehog medulloblastoma.正确实施的靶向治疗：针对音猬因子髓母细胞瘤的直接音猬因子抑制
Neuro Oncol. 2024 Apr 5;26(4):623-624. doi: 10.1093/neuonc/noae018.
6
Blood-Brain Barrier Breakdown Determines Differential Therapeutic Outcome in Genetically Diverse Forms of Medulloblastoma.血脑屏障破坏决定了不同遗传形式的髓母细胞瘤的治疗效果差异。
Cancer Cell. 2016 Apr 11;29(4):427-429. doi: 10.1016/j.ccell.2016.03.024.
7
SHH inhibitors for the treatment of medulloblastoma.用于治疗髓母细胞瘤的音猬因子（SHH）抑制剂
Expert Rev Neurother. 2015;15(7):763-70. doi: 10.1586/14737175.2015.1052796. Epub 2015 May 31.
8
Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma.福替替尼是治疗转移性 sonic hedgehog 型髓母细胞瘤的有效疗法。
Cancer Res. 2015 Jan 1;75(1):134-46. doi: 10.1158/0008-5472.CAN-13-3629. Epub 2014 Nov 12.
9
Medulloblastoma: signalling a change in treatment.髓母细胞瘤：预示治疗方式的改变。
Lancet Oncol. 2004 Apr;5(4):209-18. doi: 10.1016/S1470-2045(04)01424-X.
10
PI-3K Inhibitors Preferentially Target CD15+ Cancer Stem Cell Population in SHH Driven Medulloblastoma.PI-3K抑制剂优先靶向SHH驱动的髓母细胞瘤中的CD15+癌症干细胞群体。
PLoS One. 2016 Mar 3;11(3):e0150836. doi: 10.1371/journal.pone.0150836. eCollection 2016.
引用本文的文献
1
Stem Cells in Cancer: From Mechanisms to Therapeutic Strategies.癌症中的干细胞：从机制到治疗策略
Cells. 2025 Apr 3;14(7):538. doi: 10.3390/cells14070538.
2
Identification of HDAC4 as a potential therapeutic target and prognostic biomarker for ZFTA-fused ependymomas.鉴定 HDAC4 作为 ZFTA 融合性室管膜瘤的潜在治疗靶点和预后生物标志物。
Cancer Gene Ther. 2023 Aug;30(8):1105-1113. doi: 10.1038/s41417-023-00616-z. Epub 2023 Apr 11.
3
Multidisciplinary Management of Medulloblastoma: Consensus, Challenges, and Controversies.髓母细胞瘤的多学科管理：共识、挑战与争议
Methods Mol Biol. 2022;2423:215-235. doi: 10.1007/978-1-0716-1952-0_19.
4
NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.NBM-BMX，一种组蛋白去乙酰化酶8（HDAC8）抑制剂，通过下调β-连环蛋白/c-Myc/SOX2信号通路和上调p53介导的O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）抑制作用来克服多形性胶质母细胞瘤中的替莫唑胺耐药性。
Int J Mol Sci. 2021 May 31;22(11):5907. doi: 10.3390/ijms22115907.
5
The multilayer community structure of medulloblastoma.髓母细胞瘤的多层群落结构。
iScience. 2021 Mar 26;24(4):102365. doi: 10.1016/j.isci.2021.102365. eCollection 2021 Apr 23.
本文引用的文献
1
A large-scale drug screen identifies selective inhibitors of class I HDACs as a potential therapeutic option for SHH medulloblastoma.一项大规模药物筛选发现，选择性抑制 I 类组蛋白去乙酰化酶可作为治疗 SHH 型髓母细胞瘤的潜在治疗选择。
Neuro Oncol. 2019 Sep 6;21(9):1150-1163. doi: 10.1093/neuonc/noz089.
2
Irreversible growth plate fusions in children with medulloblastoma treated with a targeted hedgehog pathway inhibitor.接受靶向刺猬信号通路抑制剂治疗的髓母细胞瘤患儿出现不可逆的生长板融合。
Oncotarget. 2017 Sep 1;8(41):69295-69302. doi: 10.18632/oncotarget.20619. eCollection 2017 Sep 19.
3
Phase I study of oral sonidegib (LDE225) in pediatric brain and solid tumors and a phase II study in children and adults with relapsed medulloblastoma.口服 sonidegib（LDE225）在儿科脑肿瘤和实体瘤中的 I 期研究，以及在复发型髓母细胞瘤患儿和成人中的 II 期研究。
Neuro Oncol. 2017 Oct 19;19(11):1542-1552. doi: 10.1093/neuonc/nox109.
4
Selective targeting of HDAC1/2 elicits anticancer effects through Gli1 acetylation in preclinical models of SHH Medulloblastoma.在 SHH 髓母细胞瘤的临床前模型中，通过Gli1 乙酰化选择性靶向 HDAC1/2 可发挥抗癌作用。
Sci Rep. 2017 Mar 9;7:44079. doi: 10.1038/srep44079.
5
Vismodegib Exerts Targeted Efficacy Against Recurrent Sonic Hedgehog-Subgroup Medulloblastoma: Results From Phase II Pediatric Brain Tumor Consortium Studies PBTC-025B and PBTC-032.维莫德吉对复发性音猬因子亚组髓母细胞瘤具有靶向疗效：来自儿科脑肿瘤协作组II期研究PBTC-025B和PBTC-032的结果
J Clin Oncol. 2015 Aug 20;33(24):2646-54. doi: 10.1200/JCO.2014.60.1591. Epub 2015 Jul 13.
6
Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition.SHH 型髓母细胞瘤的基因组测序预测了 smoothened 抑制与基因型相关的反应。
Cancer Cell. 2014 Mar 17;25(3):393-405. doi: 10.1016/j.ccr.2014.02.004.
7
Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas.髓母细胞瘤的分子亚型：WNT、SHH、Group 3 和 Group 4 髓母细胞瘤的转录组、遗传异常和临床数据的国际荟萃分析。
Acta Neuropathol. 2012 Apr;123(4):473-84. doi: 10.1007/s00401-012-0958-8. Epub 2012 Feb 23.
8
Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma.在髓母细胞瘤中，平滑肌瘤突变赋予对刺猬信号通路抑制剂的抗性。
Science. 2009 Oct 23;326(5952):572-4. doi: 10.1126/science.1179386. Epub 2009 Sep 2.
9
Suberoylanilide hydroxamic acid is effective in preclinical studies of medulloblastoma.
J Neurooncol. 2006 Sep;79(3):259-70. doi: 10.1007/s11060-006-9142-0. Epub 2006 Apr 28.
10
Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine.环杷明可逆转平滑蛋白和patched基因致癌突变的影响。
Nature. 2000 Aug 31;406(6799):1005-9. doi: 10.1038/35023008.
Zotero 插件